FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W178117945> ?p ?o ?g. }

• W178117945 abstract "Introduction Adult acute myeloid leukemia (AML) exemplifies the challenges of modern cancer drug discovery and development in that molecularly targeted therapies are yet to be translated into clinical use. No effective second-line therapy exists once standard chemotherapy fails. While many genetic events have been linked with the onset and progression of AML, the fundamental disease mechanisms remain poorly understood. There is significant genomic and molecular heterogeneity among patients. Several targeted therapies have been investigated for improved second-line AML therapy but none has been approved for clinical use to date. It would be critically important to identify patient subgroups that would benefit from such therapies and to identify combinations of drugs that are likely to be effective. Methods To identify and optimize novel therapies for AML, we studied 28 samples from 18 AML patients with an individualized systems medicine (ISM) approach. The ISM platform includes functional profiling of AML patient cells ex vivo with drug sensitivity and resistance testing (DSRT), comprehensive molecular profiling as well as clinical background information. Data integration was done to identify disease- and patient-specific molecular vulnerabilities for translation in the clinic. The DSRT platform comprises 306 anti-cancer agents, each tested in a dose response series. We calculated differential drug sensitivity scores by comparing AML responses to those of control cells in order to distinguish cancer-specific drug effects. Next generation RNA- and exome-sequencing was used to identify fusion transcripts and mutations that link to drug sensitivities. Results Individual AML patient samples had a distinct drug sensitivity pattern, but unsupervised hierarchical clustering of the drug sensitivity profiles of the 28 AML patient samples identified 5 functional AML drug response subtypes. Each subtype was characterized by distinct combinations of sensitivities: Bcl-2 inhibitors (e.g. navitoclax; Group 1), JAK inhibitors (e.g. ruxolitinib) (Group 2) and MEK inhibitors (e.g. trametinib) (Groups 2 and 4), PI3K/mTOR inhibitors (e.g. temsirolimus; Groups 4 and 5), broad spectrum receptor tyrosine kinase inhibitors (e.g. dasatinib) (Groups 3, 4 and 5) and FLT3 inhibitors (e.g. quizartinib, sunitinib) (Group 5). Correlation of overall drug responses with genomic profiles revealed that RAS and FLT3 mutations were significantly linked with the drug response subgroups 4 and 5, respectively. Activating FLT3 mutations contributed to sensitivity to FLT3 inhibitors, as expected, but also to tyrosine kinase inhibitors not targeting FLT3, such as dasatinib. Hence, these data point to the potential synergistic combinatorial effects of FLT3 inhibitors with dasatinib for improved therapy outcome (Figure). Early clinical translational results based on compassionate use support this hypothesis. Therefore, by combinations of drugs we expect to see synergistic drug responses that can be translated into efficacious and safe therapies for relapsed AML cases in the clinic. Clinical application of DSRT results in the treatment of eight recurrent chemorefractory patients led to objective responses in three cases according to ELN criteria, whereas four of the remaining five patients had meaningful responses not meeting ELN criteria. After disease progression, AML patient cells showed ex vivo resistance to the drugs administered to the patients, as well as significant changes in clonal architecture during treatment response. Furthermore, we saw genomic alterations potentially explaining drug resistance, such as appearance of novel fusion genes. Summary The ISM approach represents an opportunity for improving therapies for cancer patients, one patient at the time. We show that the platform can be used to identify functional groups of AML linking to vulnerabilities to single targeted drugs and, importantly, unexpected drug combinations. This information can in turn be used for personalized medicine strategies and for creating hypotheses to be explored in systematic clinical trials, both for approved and investigational drugs. Disclosures: Off Label Use: Many of the compounds included in our DSRT platform are not indicated for AML therapy. Mustjoki:BMS: Honoraria, Research Funding; Novartis: Honoraria. Porkka:Novartis: Honoraria, Research Funding; BMS: Honoraria, Research Funding. Kallioniemi:Medisapiens: Membership on an entity’s Board of Directors or advisory committees; Roche: Research Funding." @default.
• W178117945 created "2016-06-24" @default.
• W178117945 creator A5001104871 @default.
• W178117945 creator A5001822701 @default.
• W178117945 creator A5004930443 @default.
• W178117945 creator A5006604923 @default.
• W178117945 creator A5008868111 @default.
• W178117945 creator A5014441735 @default.
• W178117945 creator A5016681267 @default.
• W178117945 creator A5016772828 @default.
• W178117945 creator A5021708697 @default.
• W178117945 creator A5024066120 @default.
• W178117945 creator A5027751924 @default.
• W178117945 creator A5028786229 @default.
• W178117945 creator A5033369123 @default.
• W178117945 creator A5042781409 @default.
• W178117945 creator A5043473901 @default.
• W178117945 creator A5046041855 @default.
• W178117945 creator A5050763201 @default.
• W178117945 creator A5050873337 @default.
• W178117945 creator A5051537989 @default.
• W178117945 creator A5060810486 @default.
• W178117945 creator A5061666924 @default.
• W178117945 creator A5061939140 @default.
• W178117945 creator A5064764393 @default.
• W178117945 creator A5066591792 @default.
• W178117945 creator A5067760174 @default.
• W178117945 creator A5075076450 @default.
• W178117945 creator A5075634967 @default.
• W178117945 creator A5076616453 @default.
• W178117945 creator A5079229880 @default.
• W178117945 creator A5084326764 @default.
• W178117945 creator A5085276790 @default.
• W178117945 creator A5088858308 @default.
• W178117945 creator A5089248994 @default.
• W178117945 creator A5089828742 @default.
• W178117945 creator A5090497827 @default.
• W178117945 creator A5091008337 @default.
• W178117945 date "2013-11-15" @default.
• W178117945 modified "2023-09-26" @default.
• W178117945 title "Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling" @default.
• W178117945 doi "https://doi.org/10.1182/blood.v122.21.482.482" @default.
• W178117945 hasPublicationYear "2013" @default.
• W178117945 type Work @default.
• W178117945 sameAs 178117945 @default.
• W178117945 citedByCount "0" @default.
• W178117945 crossrefType "journal-article" @default.
• W178117945 hasAuthorship W178117945A5001104871 @default.
• W178117945 hasAuthorship W178117945A5001822701 @default.
• W178117945 hasAuthorship W178117945A5004930443 @default.
• W178117945 hasAuthorship W178117945A5006604923 @default.
• W178117945 hasAuthorship W178117945A5008868111 @default.
• W178117945 hasAuthorship W178117945A5014441735 @default.
• W178117945 hasAuthorship W178117945A5016681267 @default.
• W178117945 hasAuthorship W178117945A5016772828 @default.
• W178117945 hasAuthorship W178117945A5021708697 @default.
• W178117945 hasAuthorship W178117945A5024066120 @default.
• W178117945 hasAuthorship W178117945A5027751924 @default.
• W178117945 hasAuthorship W178117945A5028786229 @default.
• W178117945 hasAuthorship W178117945A5033369123 @default.
• W178117945 hasAuthorship W178117945A5042781409 @default.
• W178117945 hasAuthorship W178117945A5043473901 @default.
• W178117945 hasAuthorship W178117945A5046041855 @default.
• W178117945 hasAuthorship W178117945A5050763201 @default.
• W178117945 hasAuthorship W178117945A5050873337 @default.
• W178117945 hasAuthorship W178117945A5051537989 @default.
• W178117945 hasAuthorship W178117945A5060810486 @default.
• W178117945 hasAuthorship W178117945A5061666924 @default.
• W178117945 hasAuthorship W178117945A5061939140 @default.
• W178117945 hasAuthorship W178117945A5064764393 @default.
• W178117945 hasAuthorship W178117945A5066591792 @default.
• W178117945 hasAuthorship W178117945A5067760174 @default.
• W178117945 hasAuthorship W178117945A5075076450 @default.
• W178117945 hasAuthorship W178117945A5075634967 @default.
• W178117945 hasAuthorship W178117945A5076616453 @default.
• W178117945 hasAuthorship W178117945A5079229880 @default.
• W178117945 hasAuthorship W178117945A5084326764 @default.
• W178117945 hasAuthorship W178117945A5085276790 @default.
• W178117945 hasAuthorship W178117945A5088858308 @default.
• W178117945 hasAuthorship W178117945A5089248994 @default.
• W178117945 hasAuthorship W178117945A5089828742 @default.
• W178117945 hasAuthorship W178117945A5090497827 @default.
• W178117945 hasAuthorship W178117945A5091008337 @default.
• W178117945 hasConcept C114851261 @default.
• W178117945 hasConcept C126322002 @default.
• W178117945 hasConcept C143998085 @default.
• W178117945 hasConcept C207001950 @default.
• W178117945 hasConcept C26291073 @default.
• W178117945 hasConcept C2777583451 @default.
• W178117945 hasConcept C2778729363 @default.
• W178117945 hasConcept C2779134260 @default.
• W178117945 hasConcept C2779536868 @default.
• W178117945 hasConcept C2780035454 @default.
• W178117945 hasConcept C2780381907 @default.
• W178117945 hasConcept C535046627 @default.
• W178117945 hasConcept C54355233 @default.
• W178117945 hasConcept C60644358 @default.
• W178117945 hasConcept C64903051 @default.
• W178117945 hasConcept C70721500 @default.
• W178117945 hasConcept C71924100 @default.

• next